Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+ B-cell lymphoma as predicted by 89Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab

• DOI: 10.1007/s00259-015-3025-6
• Publication Date: 2015-03-19T16:43:12Z
• Authors: Kristoff Muylle; Patrick Flamen; Danielle J. Vugts; Thomas Guiot; Ghanem Ghanem; Nathalie Meuleman; Pierre Bourgeois; Bruno Vanderlinden; Guus A. M. S. van...; Hendrik Everaert; Mélanie Vaes; Dominique Bron
• Keywords: Preload

To compare using immuno-PET/CT the distribution of 89Zr-labelled rituximab without and with a preload unlabelled to assess impact preloading on tumour targeting radiation dose subsequent radioimmunotherapy 90Y-labelled in CD20+ B-cell lymphoma. Five patients lymphoma progressive disease were prospectively enrolled. All underwent three study phases: initial dosimetric phase baseline 89Zr-rituximab PET/CT imaging cold preload, followed 3 weeks later by second administration standard (250 mg/m2) injection 89Zr-rituximab, therapeutic 1 week 90Y-rituximab. tracer uptake organs lesions assessed. With calculated whole-body 90Y-rituximab was similar (mean 0.87 mSv/MBq, range 0.82–0.99 mSv/MBq) all patients. Without an increase 59 % 87 noted two preserved circulating B cells. This primarily due 12.4-fold 15-fold higher spleen preload. No significant change other depletion. consistently noticed Administration impairs radioconjugate majority eligible for radioimmunotherapy, that is previously treated rituximab-containing regimens. common practice may need be reconsidered further evaluated as rationale this high has its origin “prerituximab era”. Clinical Trial Application: CTA 2011-005474-38 Registry: EudraCT